Last updated on March 30, 2017
Mexico City, D.F. – More than one million doses of dengue vaccine has been authorized for release in private Mexico clinics.
The Federal Commission for the Protection against Sanitary Risk (COFEPRIS) authorized one million doses of the vaccine. The Dengvaxia vaccine, which was developed by the pharmaceutical company Sanofi Pasteur, is the world’s first vaccine against the mosquito-borne virus and is effective against all four sterotypes.
Eduardo Arce-Parellada, CEO of Sanofi Pasteur Mexico, says they estimate more than 250,000 people per year suffer from dengue in the country and that more than 400 million worldwide are affected each year.
He explained that, “The rate in the country has maintained an increase in recent years with a peak incidence between 2009 and 2013 reaching approximately 250,000 cases. The vaccine has been in development for more than 20 years and will be an important tool in the fight against this pandemic.”
Olivier Charmeil, Sanofi’s executive vice president explained, “Mexico is one of the countries where we started our clinical trials, which has been associated with the program from the very beginning and whose regulatory authority is certified by the WHO.”
Charmeil said Mexican regulators had given their green light based on results from a clinical development program involving over 40,000 people from 15 countries of different ages, geographic and epidemiological settings as well as of varied ethnic and socio-economic backgrounds.
The vaccine is only available to the private market for patients aged 9 to 45 who live in areas where the disease is endemic. Young children, a population considered most at risk, do not have approval for the vaccine. Tourists are also exempt.
Dengue fever burden in Asia continues to be the highest globally with an estimated 67 million people being sickened by the dengue annually.